Clinical Trial Detail

NCT ID NCT02793583
Title Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

diffuse large B-cell lymphoma

Therapies

Umbralisib

Ublituximab + Umbralisib

Age Groups: adult

No variant requirements are available.